NOVAREMED-AG
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, announced today that by mutual agreement with the Board of Directors, Dr. Nicholas Draeger has decided to step down as CEO and member of the Board of Directors and will serve as a senior advisor to Novaremed in order to ensure a smooth leadership transition. The search for a full-time successor to Dr. Draeger has been initiated.
Mr. Subhasis Roy, COO, and Dr. Sara Mangialaio, CMO and Head of R&D, will be assuming responsibilities for the company’s day to day operations and all clinical development work, respectively, effective immediately.
Mr. Subhasis Roy has served as the COO of Novaremed since April 2018 and has over 20 years of experience in healthcare investment banking. Prior to Novaremed, Mr. Roy held senior roles at Sirius Healthcare Partners, UBS, HSBC and DKB, among other firms.
Dr. Sara Mangialaio has served as the CMO and Head of R&D at Novaremed since October 2017 and has over 20 years of experience in the pharmaceutical industry. Dr. Mangialaio held senior roles at Actelion and Novartis and has established experience in the planning and execution of clinical trials.
“We’d like to thank Dr. Draeger for his service and contributions to Novaremed. Our entire management team and board remain committed to developing NRD.E1 and to carrying out our global Phase 2b study,” stated Mr. Harry Welten, Chairman of the Board of Directors of Novaremed.
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and reincorporated as Novaremed AG in Switzerland late 2017. Novaremed is developing NRD.E1, an orally-active non-opioid small molecule with a new mechanism of action for the treatment of Diabetic Neuropathic Pain (DPN). In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DPN, expected to start in Q2/3 2020. For more information, visit www.novaremed.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005621/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PIF and FIFA forge partnership for FIFA Club World Cup 2025™5.6.2025 19:00:00 CEST | Press release
PIF joins inaugural FIFA Club World Cup™ ahead of kick-off on June 14 in Miami The partnership expands PIF’s global footprint in sports and reflects a shared commitment with FIFA to fuel growth and engagement in football FIFA Club World Cup 2025™ will make history, redefining club football and bringing 32 of the world’s best clubs together for the first time PIF and FIFA today announced PIF as an official partner of FIFA Club World Cup 2025™, which will take place in the U.S. from June 14 to July 13, 2025. The partnership reflects FIFA and PIF’s shared vision to enable greater participation in sports by unlocking new opportunities, fostering innovation and engaging fans around the world. With a focus on youth, the partnership will provide opportunities for young people, supporting FIFA in its efforts to engage and inspire at a grassroots level. The new FIFA Club World Cup 2025™ marks a fresh chapter for club football on the global stage. It will feature 32 of the world’s top football c
Orange Logic Appoints Ben Colenso as Managing Director, EMEA5.6.2025 18:41:00 CEST | Press release
Strategic hire underscores company’s growth and commitment to the region Orange Logic, the leader in digital asset management and content orchestration, today announced the appointment of Ben Colenso as Managing Director for EMEA. Based in the UK, Colenso will spearhead Orange Logic’s regional strategy, customer enablement, and market expansion efforts, as the company accelerates its global footprint. Colenso brings 20 years of experience in technology and media production, having most recently led the technology strategy for Hogarth, WPP’s content experience company. Known for solving complex problems for some of the world’s most iconic brands with his customer-centric approach, Colenso will play a critical role in strengthening Orange Logic’s presence and partnerships across EMEA which span customers such as ITV, Pearson, GSK, Ubisoft and Tourism Ireland amongst others. “Ben’s appointment reflects our deep commitment to EMEA, where we continue to see strong momentum and increasing de
Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 20405.6.2025 17:22:00 CEST | Press release
All SAP software licensees can now easily extend the useful life and maximize the full value of their current, proven and stable mission-critical systems and enjoy total maintenance savings of up to 90% without the requirement of a costly and risky migration to S/4HANA on RISE Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it has extended full support coverage for all SAP ECC 6.0 and S/4HANA releases through 2040, without any need to complete a migration to S/4HANA on RISE as required by SAP for clients who want to remain on SAP’s Annual Support and receive full support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605581964/en/ Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 2040 Rimini S
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform5.6.2025 16:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice® fully human antibody platform family. It underscores the continued advancement of Biocytogen’s comprehensive global patent strategy and highlights the innovation and international recognition of the company’s proprietary technologies. RenMab™ mice are a core member of Biocytogen’s independently developed RenMice® fully human antibody discovery platform family. Using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts.
Pink Bows Foundation Expands Showstop® Procedure Training and Certification Across Europe5.6.2025 16:00:00 CEST | Press release
Denmark’s Roskilde Festival hosts two days of Showstop Procedure training, 25 years after 9 tragic deaths Pink Bows Foundation (“organization” or “Pink Bows”) announced today another milestone - its global expansion - growing its impact with the successful delivery of two additional accredited Showstop® Procedure courses hosted by Denmark’s Roskilde Festival and attended by Paleo Festival and Engage Festival, among other event organizers and managers across Europe. Other sold-out training sessions took place in Dublin and Glasgow, with further courses to be announced for Fall 2025. “Never stop learning and improving. I believe that we have a good system for stopping a show at Roskilde Festival and RFX. We still hosted a course on Showstop procedure today on behalf of Pink Bows Foundation,” said Morton Therkilsden, Director of Safety, Roskilde Festival. Since its launch in Houston, Texas in March 2025, Pink Bows has trained 200 event professionals across the US, UK, Ireland and Denmark.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom